• La Jolla Receives European Commission Approval for Giapreza americanpharmaceuticalreview
    September 03, 2019
    La Jolla announced that the European Commission (EC) has approved GIAPREZA™ (angiotensin II) for the treatment of refractory hypotension in adults with septic or other distributive shock...
PharmaSources Customer Service